For each year of the Track Record Period, purchases from our five largest suppliers accounted for 34.6%, 39.6% and 38.1% of our total purchases, and purchases from our largest supplier accounted for 14.5%, 14.5% and 13.8% of our total purchases.
Summary · p. 8
For each year of the Track Record Period, the purchases from our five largest suppliers for our cross-border social e-commerce business accounted for 49.5%, 54.6% and 55.7% of our total purchases of our cross-border social e-commerce business.
Summary · p. 8
During the Track Record Period, our top five suppliers were primarily digital marketing service providers.
In 2023 and 2024, our purchases from our five largest suppliers in each period in aggregate amounted to RMB137.1 million and RMB32.6 million, respectively, representing 66.3% and 47.5% of our total corresponding purchases in such periods, respectively, and our purchases from the largest supplier in each period accounted for 33.0% and 16.0% of our total corresponding purchases, respectively.
Business · p. 370
We do not rely on any of such suppliers as we believe that adequate alternative sources for such supplies of relevant services/raw materials (such as active pharmaceutical ingredient of our drug candidates) exist, and we have developed alternative sourcing strategies for these supplies.
Business · p. 369
Our material increase in the expenses attributable to the five largest suppliers during the Track Record Period is in line with the advancement of clinical trials of our Core Product.
In each of the years ended December 31, 2022, 2023 and 2024, our aggregate purchases from our five largest raw material suppliers amounted to RMB842.5 million, RMB957.1 million, and RMB948.0 million, respectively, representing 24.1%, 27.0%, and 28.0% of our cost of sales for these respective periods.
Business · p. 322
We generally contract with more than one supplier for each major type of raw material, except for very few specified raw materials for which we contract with exclusive suppliers.
Business · p. 314
During the Track Record Period, the major APIs we procured were irbesartan, valsartan, imrecoxib, paclitaxel, capecitabine and febuxostat, and the purchase prices of these major APIs did not experience any material unfavorable fluctuations.
For each period during the Track Record Period, our purchase from our five largest suppliers amounted to US$14.9 million, US$3.7 million and US$6.2 million, respectively, accounting for 48.4%, 28.4% and 56.2% of our total purchases, respectively.
Business · p. 418
Specifically, we have identified two to five alternative suppliers in the market and may engage them to ensure a stable and sufficient supply for the production of our products and product candidates once approved.
Business · p. 422
As of the Latest Practicable Date, some of our key raw materials including enzymes, plastic tubes and primers were imported from three suppliers located outside Singapore.
During the Track Record Period, our purchases from the five largest suppliers in each year accounted for 21.3%, 20.3% and 16.3% of our total purchases in the respective year; and purchases from our largest supplier in each year accounted for 5.4%, 5.3% and 6.0% of our total purchases in the respective year.
Summary · p. 6
During the Track Record Period, we maintained stable business relationships with our five largest suppliers in each year.
Business · p. 199
We shortlisted a panel of suppliers and have established long-term stable partnerships with key suppliers.
In each of 2022, 2023 and 2024, the total purchases from our five largest suppliers in the aggregate accounted for 18.6%, 18.4% and 18.2%, respectively, of our total purchases, and our purchases from our largest supplier accounted for 5.0%, 5.2% and 4.5%, respectively, of our total purchases.
Summary · p. 9
Our purchases from Supplier A declined during the Track Record Period due to our efforts to diversify our supplier base and reduce our reliance on our largest supplier.
Business · p. 195
We typically have multiple suppliers for each of our main food ingredients to minimize any potential disruption in our operations, maintain sourcing stability, avoid over-reliance risk, and secure competitive prices from suppliers.
In 2022, 2023 and 2024, purchase from each of the top five suppliers of the continuing operation amounted to RMB5,574.4 million, RMB8,608.1 million and RMB4,915.1 million, accounting for 47.2%, 34.4% and 56.2% of our total purchase for the corresponding years, respectively.
Business · p. 266
According to Frost & Sullivan, the top ten silicon wafer manufacturers globally accounted for 89.4% of the world's production in 2022.
Business · p. 267
In addition, during the Track Record Period, we successfully managed dependency on any single supplier by cooperating with more major players in the PV industry, which is evidenced by the changing composition of our top five suppliers of our continuing operation.
In 2022, 2023 and 2024, the aggregate purchases attributable to our five largest suppliers for each year of the Track Record Period amounted to RMB336.7 million, RMB318.7 million and RMB347.4 million, respectively, representing 68.5%, 66.3% and 56.7% of our total purchases for the corresponding years.
Summary · p. 13
Purchases attributable to our single largest supplier amounted to RMB174.1 million, RMB189.0 million and RMB153 million for the same years, accounting for 35.4%, 39.4% and 24.9% of our total purchases for the corresponding years.
Business · p. 260
In addition to maintaining strong ties with our major suppliers, we are proactively expanding our supplier network to broaden our sourcing channels for key components, thereby reducing dependency on our existing suppliers and enhancing our supply chain resilience.
For the years ended December 31, 2023 and 2024, our purchases from our five largest suppliers in each year in aggregate accounted for 42.0% and 67.1% of our total purchases for the respective year, respectively.
Business · p. 423
Our purchases from our largest supplier in each year accounted for 12.5% and 25.7% of our total purchases for the respective year, respectively.
Business · p. 423
We have maintained stable business relationships with our major suppliers.
In 2021, 2022, 2023 and 2024, purchases from our largest supplier in each year during the Track Record Period amounted to RMB665.0 million, RMB1,326.6 million, RMB433.9 million and RMB674.8 million, representing 40.8%, 38.2%, 14.3% and 19.1% of our total amount of purchase during the respective years, while purchases from our five largest suppliers in each year during the Track Record Period amounted to RMB1,079.3 million, RMB2,230.0 million, RMB1,368.1 million and RMB1,736.4 million, representing 66.1%, 64.2%, 45.0% and 49.2% of our total amount of purchase during the respective years.
Business · p. 294
Unless specifically otherwise required by our customers, we maintain alternative suppliers for all of our key raw materials.
For each of FY2022, FY2023 and 9M2024, Yihai Kerry became our largest supplier, and our purchase with Yihai Kerry amounted to approximately RMB141.9 million, RMB282.3 million and RMB284.5 million for FY2022, FY2023 and 9M2024, representing approximately 12.5%, 25.5% and 30.5% of our total purchase, respectively.
Summary · p. 3
To the best knowledge of our Directors, Yihai Kerry granted similar district distributorship rights in Yangzhou City to not more than three companies including us.
Summary · p. 3
For FY2021, FY2022, FY2023 and 9M2024, our purchase from our largest supplier in each year/period during the Track Record Period accounted for approximately 7.5%, 12.5%, 25.5% and 30.5% of our total purchase costs, respectively, while our purchase from our five largest suppliers in each year/period during the Track Record Period in aggregate accounted for approximately 28.0%, 35.9%, 42.4% and 50.0% of our total purchase costs, respectively.
5 Supplier E See Note 5. | Polypropylene | 2021 | Prepayment Bank transfer | 7,141 3.6 89,275 45.1
Business · p. 209
To reduce the risk of price fluctuation, and as one of our internal control measures to ensure a stable supply of raw materials that satisfy our quality requirements, we have approximately three alternative suppliers within the PRC for each type of our key raw materials.
Business · p. 208
To maintain strong relationships with our key suppliers, some of whom are dominant players in the market, we typically place orders on a regular basis, regardless of periodic fluctuations in our operations.
Our five largest suppliers together accounted for 79.4%, 68.9%, 53.7% and 47.0%, respectively, of our total procurement in each year/period of the Track Record Period. Supplier A was our largest supplier in each year/period of the Track Record Period, accounting for 30.8%, 26.9%, 15.7% and 14.3% of our total procurement amount during the same periods.
Business · p. 207
In supplier selection, we primarily consider factors such as the price, the quality of the raw materials, the timing of the delivery, payment method, candidate's credit history, and feedback received from our production department.
Business · p. 207
Our Directors consider that we do not have material reliance on Mr. Santony, Mr. George Santos and/or his associates as our Group can find substitute suppliers for bauxite in Indonesia with the abundant supply of good quality bauxite locally.
Purchases from our five largest suppliers, for 2022, 2023 and the nine months ended September 30, 2024 were RMB87.4 million, RMB30.0 million and RMB22.4 million, respectively, representing 53%, 45% and 54% of our total purchase cost for the respective period.
Business · p. 354
Save for Ascendis Pharma, all of our five largest suppliers during the Track Record Period are Independent Third Parties, and none of our Directors, their respective associates nor any Shareholder who, to the knowledge of our Directors, owned more than 5% of our issued share capital as at the Latest Practicable Date, has any interest in any of our five largest suppliers during the Track Record Period.
Business · p. 354
In addition, we believe that adequate alternative sources for such supplies exist and we have developed alternative sourcing strategies for these supplies.
Since the Core Product is used exclusively with the auto-injector produced by such marketing authorization holder, we expect to rely on its auto-injector supply before we establish our collaborative local manufacturing capability with local CDMO.
Business · p. 329
The import medical device registration application for the auto-injector was submitted by a third-party marketing authorization holder to the NMPA in June 2023 and has been approved in April 2024, ahead of the expected BLA approval date of the Core Product for PGHD in the second half of 2025.
In 2021, 2022 and 2023 and the six months ended June 30, 2024, purchases from our five largest suppliers in each year or period during the Track Record Period accounted for 82.3%, 82.2%, 90.5% and 71.6% of our total purchases for such year or period during the Track Record Period.
Summary · p. 11
Purchases from our partner factories accounted for the majority of our purchases during the Track Record Period.
Business · p. 219
As we possess the key know-how and patents, we can work with new factories and set up the production lines within approximately three months.
For each financial year/period during the Track Record Period, purchases from our top five suppliers collectively accounted for approximately 99.6%, 97.3%, 98.6% and 99.5% of our total purchases, respectively, and the purchases from our largest supplier accounted for approximately 35.1%, 86.2%, 87.7% and 93.5% of our total purchases, respectively.
Business · p. 314
The significant increase in the purchases from our largest supplier from approximately 35.1% for FY2021 to approximately 86.2%, 87.7% and 93.5% for FY2022, FY2023 and 6M2024, respectively, was primarily attributable to (i) the supply of hardware parts and components in respect of the increase in the sale of our other products of hardware parts and components during FY2022;
Business · p. 314
according to F&S, the hardware and certain software components we purchased externally for our projects of ICV simulation testing platforms and ICV data platforms and other products are generally generic products which are readily available from numerous hardware manufacturers and software developers in the market.
For each year/period of the Track Record Period, our purchases made to our five largest suppliers amounted to approximately RMB539.3 million, RMB882.1 million, RMB1,296.6 million and RMB654.5 million, respectively, representing approximately 30.2%, 49.0%, 64.5% and 69.8% of our total purchases for the corresponding year/period, respectively, while our purchases made to our largest supplier in each year during the Track Record Period amounted to approximately RMB211.4 million, RMB509.5 million, RMB916.2 million and RMB495.1 million respectively, representing approximately 11.8%, 28.3%, 45.6% and 52.8% of our total purchases for the corresponding year/period, respectively.
Business · p. 266
Our total purchases with our largest supplier has increased steadily throughout the Track Record Period due to the fact that we began sourcing ethylene oxide with it in FY2022 for our production of concrete admixtures; as our concrete admixture business grew, so did our purchase of ethylene oxide from our largest supplier.
Business · p. 266
Such practice enhances our bargaining power on raw materials prices, avoid reliance on one single supplier, and helps us to identify the best value-for-money option.
For FY2021, FY2022, FY2023 and 6M2024, our purchases from our five largest suppliers for each year/period during the Track Record Period accounted for approximately 90.7%, 92.7%, 94.3% and 92.4% of our total purchases respectively, and our purchases from our largest supplier for each year/period during the Track Record Period accounted for approximately 56.8%, 42.6%, 49.6% and 48.5% of our total purchases, respectively.
Business · p. 221
The algal oil DHA raw materials of our finished algal oil DHA products were all sourced from DSM Group (including DSM Shanghai) and the probiotics raw materials of our finished probiotics products were all sourced from the Probiotics Raw Material Supplier.
Business · p. 227
Considering the market position of DSM Group and the Probiotics Raw Material Supplier, Frost & Sullivan is of the view that it is an industry norm for brand owner of algal oil DHA products and probiotics products like our Group to have material reliance on the principal raw material suppliers like DSM Group and the Probiotics Raw Material Supplier, and it is not commercially realistic for our Group to diversify our reliance.
For FY2021, FY2022, FY2023 and 6M2024, the revenue contribution by sales of our New Zealand DHA Products/U.S. DHA Products in aggregated accounted for approximately 67.8%/25.5% and 61.3%/33.6% of our total revenue, respectively
Business · p. 227
As such, our Directors are of the view that our Group has material reliance on Shanghai Trilives, Confidence Group and the New Zealand Processing Company.
Business · p. 228
As such, our Directors are of the view that our reliance on Shanghai Trilives, Confidence Group and the New Zealand Processing Companies is mutual.